Cancer immunotherapy has received considerable attention because of a variety of exciting clinical outcomes in recent years. At the interface of cancer immunotherapy and bioengineering, there are many opportunities to further improve the treatment efficacy or address current challenges in immunotherapy. Cellular bioparticulates as promising carriers of immunomodulators have attracted much attention due to their inherent biocompatibility and unique biological properties. This Topical Review highlights recently reported studies utilizing bioparticulates for cancer immunotherapy, including engineered red blood cells (RBC) and RBC membrane coated particles, engineered T-cells, engineered platelets, and engineered microbes.